Mesa Laboratories (MLAB)
NASDAQ:MLAB
Want to see MLAB full AI Analyst Report?
Top Page
Mesa Laboratories
(NASDAQ:MLAB)
Select Model
Select Model
Rating:61Neutral
Price Target:
$111.00
▲(7.70% Upside)
Action:Reiterated
Date:06/16/26
The score is driven primarily by resilient cash generation and improving financial trajectory (strong 2026 revenue growth and a return to profitability), supported by a constructive technical uptrend. These positives are materially offset by expensive valuation (very high P/E with a low dividend yield) and the company’s history of earnings volatility.
Positive Factors
Recurring consumable revenue
Mesa’s core sterilization and clinical genomics products are consumable, driving repeat purchases from regulated hospitals and labs. This creates predictable, recurring revenue streams tied to compliance needs, supporting volume stability and long-term cash visibility across inspection and accreditation cycles.
Negative Factors
Earnings volatility
Large swings in profitability reduce predictability for cash flow and returns. Intermittent heavy losses can interrupt investment plans, strain stakeholder confidence, and complicate long-range forecasting, implying higher operational and execution risk relative to more stable peers.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumable revenue
Mesa’s core sterilization and clinical genomics products are consumable, driving repeat purchases from regulated hospitals and labs. This creates predictable, recurring revenue streams tied to compliance needs, supporting volume stability and long-term cash visibility across inspection and accreditation cycles.
Read all positive factors
Mesa Laboratories (MLAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$542.27M
Dividend Yield0.79%
Average Volume (3M)148.03K
Price to Earnings (P/E)79.8
Beta (1Y)1.34
Revenue Growth3.38%
EPS GrowthN/A
CountryUS
Employees741
SectorTechnology
Sector Strength88
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)1.23
Shares Outstanding5,524,931
10 Day Avg. Volume101,777
30 Day Avg. Volume148,032
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.62
Price to Sales (P/S)1.96
P/FCF Ratio12.32
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit4.21
Enterprise Value/Ebitda15.36
Forecast
1Y Price Target
$94.00Price Target Upside-8.79% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)8.67
Revenue Forecast (FY)$260.44M
Mesa Laboratories Business Overview & Revenue Model
Company Description
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control ...
How the Company Makes Money
Mesa Laboratories makes money by selling specialized consumable products, instruments, and services used to validate, monitor, and document critical processes in regulated environments.
Key revenue streams include:
1) Sterilization & Disinfection...
Mesa Laboratories Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
55
Neutral
Cash Flow
74
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 249.13M | 240.98M | 216.19M | 219.08M | 184.34M |
| Gross Profit | 158.27M | 150.87M | 133.25M | 133.69M | 109.09M |
| EBITDA | 35.28M | 42.35M | -238.38M | 37.52M | 32.53M |
| Net Income | 6.71M | -1.97M | -254.25M | 930.00K | 1.87M |
Balance Sheet | |||||
| Total Assets | 427.75M | 433.35M | 446.80M | 661.83M | 707.37M |
| Cash, Cash Equivalents and Short-Term Investments | 26.93M | 27.32M | 28.21M | 32.91M | 49.35M |
| Total Debt | 168.83M | 181.47M | 231.30M | 186.14M | 221.13M |
| Total Liabilities | 241.50M | 273.52M | 301.40M | 268.35M | 313.57M |
| Stockholders Equity | 186.25M | 159.83M | 145.39M | 393.48M | 393.80M |
Cash Flow | |||||
| Free Cash Flow | 39.58M | 42.31M | 41.57M | 23.44M | 34.79M |
| Operating Cash Flow | 42.83M | 46.81M | 44.13M | 27.98M | 39.22M |
| Investing Cash Flow | -3.25M | -4.50M | -81.31M | -9.49M | -305.23M |
| Financing Cash Flow | -41.85M | -44.51M | 32.84M | -33.33M | 52.58M |
Mesa Laboratories Technical Analysis
Neutral
103.06
Price Trends
101.74
Negative
95.03
Positive
85.35
Positive
Market Momentum
-1.91
Positive
46.86
Neutral
33.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Neutral. The current price of 103.06 is above the 20-day moving average (MA) of 102.17, above the 50-day MA of 101.74, and above the 200-day MA of 85.35, indicating a neutral trend. The MACD of -1.91 indicates Positive momentum. The RSI at 46.86 is Neutral, neither overbought nor oversold. The STOCH value of 33.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MLAB.
Mesa Laboratories Risk Analysis
Mesa Laboratories disclosed 94 risk factors in its most recent earnings report. Mesa Laboratories reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Uncertainties related to the use of artificial intelligence ("AI") in our business may result in harm to our business and reputation. Q1, 2026
2.
Uncertainties related to the use of artificial intelligence ("AI") in our business may result in harm to our business and reputation. Q1, 2026
3.
Evolving cybersecurity regulations, including the European Union's Cyber Resilience Act, may increase our compliance costs and require changes to our products and processes. Q1, 2026
Mesa Laboratories Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $939.62M | 20.88 | 9.64% | ― | 10.87% | ― | |
68 Neutral | $983.89M | 34.66 | 8.90% | 1.07% | 11.42% | 5.37% | |
64 Neutral | $855.82M | -27.44 | -41.18% | ― | 86.66% | -97.48% | |
62 Neutral | $259.23M | 67.04 | 2.37% | 2.25% | 4.82% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | $542.27M | 79.80 | 3.71% | 0.79% | 3.38% | ― | |
59 Neutral | $1.78B | 298.69 | 1.77% | ― | 7.51% | 93.82% |
* Technology Sector Average
MLAB
Mesa Laboratories
98.15
2.52
2.64%
DAKT
Daktronics
19.46
4.43
29.47%
LPTH
Lightpath Technologies
13.63
10.49
334.08%
LYTS
Lsi Industries
26.80
10.22
61.59%
RELL
Richardson Electronics
18.06
8.57
90.29%
VPG
Vishay Precision Group
134.02
106.03
378.81%
Mesa Laboratories Corporate Events
Executive/Board Changes
Mesa Laboratories Promotes Lyndsey Crennen to Chief Accounting Officer
Positive
Jun 15, 2026
On June 11, 2026, Mesa Laboratories, Inc.’s board appointed longtime company executive Lyndsey Crennen as Chief Accounting Officer, elevating her from her current role as Corporate Controller. Crennen, a Certified Public Accountant with more...
Executive/Board Changes
Mesa Laboratories CEO Gary Owens Announces Planned Departure
Neutral
Mar 23, 2026
Mesa Laboratories, Inc. announced on March 9, 2026, that President and Chief Executive Officer Gary Owens will depart the company effective on or about April 13, 2026, and subsequently entered into a Transition Agreement on March 20, 2026, under w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.